Active surveillance protocol in prostate cancer in Portugal

被引:1
|
作者
Gaspar, S. R. da Silva [1 ]
Fernandes, M. [1 ]
Castro, A. [1 ]
Oliveira, T. [1 ]
Dias, J. Santos [1 ]
dos Reis, J. Palma [1 ]
机构
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Urol, Lisbon, Portugal
来源
ACTAS UROLOGICAS ESPANOLAS | 2022年 / 46卷 / 06期
关键词
Active surveillance; Prostate cancer; Watchful waiting; Portugal; MRI; Biopsy; VERSION; 2; MEN; COMPLICATIONS; MANAGEMENT; BIOPSIES;
D O I
10.1016/j.acuro.2021.01.010
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine clinical practice patterns in locally managing patients under an active surveillance protocol among Portuguese urologists. Introduction: Prostate cancer (PCa) is a heterogeneous disease with many prostate adeno-carcinomas being indolent and a low probability of ever causing symptoms or death. Active surveillance (AS) is a form of conservative management aimed to reduce over-treatment for low-risk PCa patients. Over the years, experience with AS has grown considerably and is now standard in some countries, however a universal protocol still does not exist. Methods: Nationwide anonymous e-survey concerning habits and practices on AS among Portu-guese urologists, that consisted of 12 questions and was sent electronically to all 368 current members of the Portuguese Urological Association. Results: 56 urologists were surveyed (15.21% answer rate), evenly distributed geographically and allocated according to years of experience as well as number of PCa patients managed monthly. The vast majority of respondents recommends AS to their patients, particularly ISUP grade 1 patients, whose PSA serum level is bellow 20ng/mL. Observance of AS programs by patients was not in question but concerns exist over psychological morbidity while harboring disease. Majority believed that international guidelines surveillance protocols were adequate and sufficient, but there are some constraints concerning availability of periodic MRIs and re -biopsy needs. Conclusions: AS seems to be sustained in urologist clinical practice, although patients still lag to adhere and choose for active treatment. AS may not be an easy choice for patients and clinicians due to uncertainty of disease progression, risk of loss to follow-up and repeated biopsies but is also a cause for anxiety, depression, uncertainty and a perception of danger. (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:329 / 339
页数:11
相关论文
共 50 条
  • [21] Active surveillance for prostate cancer: is it too active?
    Ehdaie, Behfar
    BJU INTERNATIONAL, 2016, 118 (03) : 343 - 343
  • [22] MRI and Active Surveillance for Prostate Cancer
    Porreca, Angelo
    Colicchia, Michele
    Busetto, Gian Maria
    Ferro, Matteo
    DIAGNOSTICS, 2020, 10 (08)
  • [23] The economics of active surveillance for prostate cancer
    Dall'Era, Marc A.
    CURRENT OPINION IN UROLOGY, 2013, 23 (03) : 278 - 282
  • [24] Active Surveillance for Prostate Cancer: Is It Safe?
    Robinson, S.
    Laniado, M.
    Karim, O.
    Motiwala, H.
    UROLOGY, 2012, 80 (03) : S291 - S291
  • [25] Active surveillance for prostate cancer: A review
    Klotz L.
    Current Urology Reports, 2010, 11 (3) : 165 - 171
  • [26] Understanding Active Surveillance for Prostate Cancer
    Lai, Lillian Y.
    Shahinian, Vahakn B.
    Oerline, Mary K.
    Kaufman, Samuel R.
    Skolarus, Ted A.
    Caram, Megan E., V
    Hollenbeck, Brent K.
    JCO ONCOLOGY PRACTICE, 2021, 17 (11) : 678 - +
  • [27] Active surveillance for prostate cancer Preface
    Dall'Era, Marc A.
    Davies, Benjamin J.
    Eggener, Scott
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2018, 7 (02) : 195 - 196
  • [28] Prostate cancer: a review of active surveillance
    Lund, Lars
    Svolgaard, Niels
    Poulsen, Mads Hvid
    RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 107 - 112
  • [29] Active surveillance for prostate cancer: an update
    Merriel, Sam
    TRENDS IN UROLOGY & MENS HEALTH, 2020, 11 (01) : 8 - 11
  • [30] An integrative active surveillance of prostate cancer
    Dunn, Marisa
    Mirda, Danielle
    Whalen, Michael J.
    Kogan, Mikhail
    EXPLORE-THE JOURNAL OF SCIENCE AND HEALING, 2022, 18 (04) : 483 - 487